✦ LIBER ✦

328 POSTER Phase II study of MTOR-inhibitor RAD001 and erlotinib for advanced, gemcitabine-refractory pancreatic cancer

✍ Scribed by M. Javle; D. Fogelman; A. Kaseb; G. Varadhachary; R. Wolff; J. Abbruzzese

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

A phase II study of erlotinib in gemcita

✍ Renouf, D.J.; Tang, P.A.; Hedley, D.; Chen, E.; Kamel-Reid, S.; Tsao, M.S.; Tran 📂 Article 📅 2014 🏛 Elsevier Science 🌐 English ⚖ 435 KB

A phase II study of bevacizumab plus erl

✍ Andrew H. Ko; Alan P. Venook; Emily K. Bergsland; R. Kate Kelley; W. Michael Kor 📂 Article 📅 2010 🏛 Springer 🌐 English ⚖ 266 KB

6603 A phase II study of erlotinib in pa

✍ Iyer, R.; Khushalani, N.; Tan, W.; Litwin, A.; LeVea, C.; Hutson, A.; Tucker, C. 📂 Article 📅 2009 🏛 Elsevier Science 🌐 English ⚖ 46 KB

6567 POSTER A Phase II Trial of Erlotini

✍ Hwang, I.G.; Jang, J.S.; Kang, J.H.; Lee, G.W.; Go, S.I.; Kang, M.H.; Oh, S.Y.; 📂 Article 📅 2011 🏛 Elsevier Science 🌐 English ⚖ 41 KB

Phase II Study of Gemcitabine and Erloti

✍ Philip Q. Bao; Ramesh K. Ramanathan; Alyssa Krasinkas; Nathan Bahary; Barry C. L 📂 Article 📅 2010 🏛 Springer 🌐 English ⚖ 303 KB

Erratum to: Phase II Study of Gemcitabin

✍ Philip Q. Bao; Ramesh K. Ramanathan; Alyssa Krasinkas; Nathan Bahary; Barry C. L 📂 Article 📅 2011 🏛 Springer 🌐 English ⚖ 107 KB